Breaking News, Collaborations & Alliances

Rocketvax Collaborates with NIH for Clinical Trial of RVX-sCPD9 Candidate

The partnership will advance the development of a next-generation SARS-CoV-2 vaccine platform into the clinical stage.

Author Image

By: Charlie Sternberg

Associate Editor

Biotech company Rocketvax AG’s RVX-sCPD9 candidate for the prevention of SARS-CoV-2 has been selected to be part of Project NextGen, an initiative by the U.S. Department of Health and Human Services aimed at advancing a pipeline of new, innovative vaccines providing broader and more durable protection against COVID-19.   As part of Project NextGen, the National Institute of Allergy and Infectious Diseases (NIAID), which is a part of the National Institutes of Health, will support a Phase 1 cli...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters